- Investing Ideas
- U.S. Pharmaceuticals & Biotech Top Growth Stocks
U.S. Pharmaceuticals & Biotech Top Growth Stocks
Results
40
40 companies
Travere Therapeutics
Market Cap: US$2.6b
A biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States.
TVTX
US$28.47
7D
1.0%
1Y
47.7%
Axsome Therapeutics
Market Cap: US$8.5b
A biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States.
AXSM
US$159.50
7D
-2.8%
1Y
33.5%
Madrigal Pharmaceuticals
Market Cap: US$9.9b
A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
MDGL
US$431.53
7D
-0.8%
1Y
31.8%
Zevra Therapeutics
Market Cap: US$649.4m
A commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States.
ZVRA
US$10.41
7D
16.6%
1Y
31.4%
Insmed
Market Cap: US$31.0b
Develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
INSM
US$139.40
7D
-7.0%
1Y
88.3%
Rhythm Pharmaceuticals
Market Cap: US$6.4b
A commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally.
RYTM
US$90.02
7D
-1.1%
1Y
75.4%
Ardelyx
Market Cap: US$1.5b
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
ARDX
US$5.99
7D
-9.9%
1Y
10.1%
Pelthos Therapeutics
Market Cap: US$81.9m
A bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens.
PTHS
US$23.25
7D
1.0%
1Y
36.8%
Achieve Life Sciences
Market Cap: US$227.8m
A late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom.
ACHV
US$4.38
7D
-4.4%
1Y
65.3%
Capricor Therapeutics
Market Cap: US$1.7b
A clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.
CAPR
US$33.57
7D
31.6%
1Y
156.8%
ARS Pharmaceuticals
Market Cap: US$879.8m
A biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally.
SPRY
US$8.38
7D
-7.3%
1Y
-31.9%
Corcept Therapeutics
Market Cap: US$3.6b
A biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.
CORT
US$33.74
7D
-5.5%
1Y
-38.7%
Alnylam Pharmaceuticals
Market Cap: US$42.8b
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.
ALNY
US$320.43
7D
-2.1%
1Y
32.2%
CG Oncology
Market Cap: US$5.3b
A late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States.
CGON
US$64.66
7D
5.0%
1Y
142.9%
CollPlant Biotechnologies
Market Cap: US$8.9m
A regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally.
CLGN
US$0.61
7D
-3.0%
1Y
-80.0%
Eton Pharmaceuticals
Market Cap: US$466.6m
A pharmaceutical company, focuses on developing and commercializing treatments for rare diseases.
ETON
US$18.09
7D
3.2%
1Y
22.4%
AC Immune
Market Cap: US$300.8m
A clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding.
ACIU
US$3.06
7D
7.7%
1Y
31.9%
Arcutis Biotherapeutics
Market Cap: US$3.0b
A biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
ARQT
US$23.95
7D
-0.7%
1Y
58.0%
Viridian Therapeutics
Market Cap: US$3.0b
Engages in discovering, developing, and commercializing treatments for serious and rare diseases.
VRDN
US$28.62
7D
-5.8%
1Y
71.9%
Kiniksa Pharmaceuticals International
Market Cap: US$3.6b
A biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally.
KNSA
US$46.31
7D
-2.0%
1Y
105.8%
Stoke Therapeutics
Market Cap: US$2.2b
An early-stage biopharmaceutical company, engages in the development of treatments for severe genetic diseases by upregulating protein expression.
STOK
US$37.94
7D
10.2%
1Y
345.3%
Belite Bio
Market Cap: US$6.8b
A clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States.
BLTE
US$173.75
7D
-2.3%
1Y
150.1%
NewAmsterdam Pharma
Market Cap: US$3.6b
A late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease.
NAMS
US$31.35
7D
0.5%
1Y
34.2%
BeOne Medicines
Market Cap: US$33.9b
An oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.
ONC
US$298.91
7D
-0.04%
1Y
19.6%
Unicycive Therapeutics
Market Cap: US$149.4m
A clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States.
UNCY
US$7.04
7D
-0.4%
1Y
19.4%
Liquidia
Market Cap: US$3.4b
A biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States.
LQDA
US$38.56
7D
12.2%
1Y
165.9%
Praxis Precision Medicines
Market Cap: US$8.3b
A clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States.
PRAX
US$296.97
7D
-4.4%
1Y
696.4%
Krystal Biotech
Market Cap: US$7.6b
A commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States.
KRYS
US$255.00
7D
-3.8%
1Y
42.9%
Gyre Therapeutics
Market Cap: US$738.0m
A pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis.
GYRE
US$8.33
7D
0.6%
1Y
-28.6%
Mirum Pharmaceuticals
Market Cap: US$5.5b
A biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases.
MIRM
US$91.75
7D
-1.4%
1Y
103.8%
Fortress Biotech
Market Cap: US$104.3m
A biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products.
FBIO
US$3.22
7D
3.9%
1Y
86.1%
Amicus Therapeutics
Market Cap: US$4.5b
A biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally.
FOLD
US$14.37
7D
0.3%
1Y
61.6%
Arcellx
Market Cap: US$6.7b
Together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States.
ACLX
US$114.36
7D
0.05%
1Y
57.3%
Benitec Biopharma
Market Cap: US$420.3m
A clinical-stage biotechnology company, focuses on the development of novel genetic medicines.
BNTC
US$12.28
7D
12.6%
1Y
-15.3%
Journey Medical
Market Cap: US$271.0m
Focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.
DERM
US$8.18
7D
1.7%
1Y
54.0%
Prothena
Market Cap: US$525.9m
A late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation.
PRTA
US$9.58
7D
-2.8%
1Y
-30.9%